Insider selling
Traded Sep 14 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +9.8% · S&P 500 −9.3% · to Nov 20
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SI · NYSE · Surgical & Medical Instruments & Apparatus
Shoulder Innovations (SI) · oqro.io/stocks/SI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$20.15−0.16 (−0.79%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Shoulder Innovations was filed in the last 90 days. The latest on record was on Mar 18, 2026.
Since 2025, Shoulder Innovations insiders reported 17 open-market purchases and 17 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2026.
In the last 90 days, 2 insiders of Shoulder Innovations (SI) reported 5 open-market sales worth $782K in total on SEC Form 4. The largest seller by value was Gilde Healthcare Holding B.V., with $594K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Shoulder Innovations (SI) was disclosed by a member of Congress in the last 12 months.
Shoulder Innovations's next results are expected on Mar 8, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+45.6% (+$6.31) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $13.84 on Nov 20, 2025 to $20.15 on Nov 20, 2026 (+45.6%). Disclosed in this range: 18 insider trades, 6 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Grand Rapids, Mi.
Last 12 months
+45.6%
Market value
$422M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 706K shares sold short (3.4% of shares outstanding), −0.5% vs the previous count, 7.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$47.3M
+49.6% vs the year before
Net income, fiscal 2025
−$40.4M
A loss for the year
Shares outstanding
20.9M
As of Oct 29, 2026
New federal contracts from the last 12 months add up to 0.36% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Insider selling
Traded Sep 14 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +9.8% · S&P 500 −9.3% · to Nov 20
The CEO of Shoulder Innovations sold $188K of Shoulder Innovations shares. The filing does not indicate a pre-arranged trading plan.
Traded Aug 20 – Aug 26, 2026 · largest single transaction ~$464KNot reported under a pre-arranged trading plan
Aug 26, 2026~$27K · 1,196 sh @ $22.60
DetailsOfficial recordAug 21, 2026~$464K · 21K sh @ $22.61
DetailsOfficial recordAug 20, 2026~$88K · 3,900 sh @ $22.60
DetailsOfficial recordAug 24, 2026~$15K · 681 sh @ $22.62
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 18, 2025, SI is up 35.7% and the index fund is up 4.5%: 31 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SI moves
Beta 0.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
On the public record for Shoulder Innovations over the 12 months to Nov 21, 2026: 1 FDA record.
No Schedule 13D or 13G filing on SI over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Shoulder Innovations reported 17 open-market purchases and 17 sales since 2025; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $78K3×3 trades | $5.47M17×17 trades |
| 2025 | $12M14×14 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
1 approval or clearance and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Revenue
$16.2M
+37.7% vs the same quarter a year earlier
Free cash flow, last 12 months
−$42.7M
This quarter −$6.98M, a year earlier −$11.4M
Net cash
$21.6M
Debt $14.8M, cash $36.4M, at Sep 30, 2026
Net income, last 12 months
−$33.4M
Operating profit covers interest 15.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. We currently offer advanced implant systems for shoulder arthroplasty. These systems are a core element of our ecosystem, which we designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Our ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration.
And 22 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 10, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Mar 8, 2027
Purchases after results
Not enough history
From Shoulder Innovations's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Shoulder Innovations's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 36.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.0% on ATS, 9.0% with other brokers), below its 26-week average of 38.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: SIGMA X2 (17.5%), UBS ATS (15.5%), INSTINCT X (11.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 10, 2026. Read the filing
78 risk factor headings in this report. There is no earlier annual report to compare it with.
From time to time, we may be party to legal proceedings that arise in the ordinary course of our business, some of which may be covered by insurance. Except for the description of legal proceedings disclosed in Note 13 to our audited financial statements, which is incorporated herein by reference, management believes that we do not have any pending legal proceedings that, separately or in the aggregate, would have a material adverse effect on our results of operations, financial condition or cash flows.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 10, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.